Immune Reconstitution and Nephrotoxicity following acute lymphoblan Acute Lymphoblastic leukemia treatment: an Acute Lymphoblastic Leukemia Survivor Toxicity And Rehabilitation (ALL-STAR) study

Project: Research

Project Details


Aims: The overall aim of the Acute Lymphoblastic Survivor Toxicity And Rehabilitation (ALL-STAR) study is to investigate the interplay existing between diagnostic characteristics, treatment, acute toxicity, and the risk of late toxicity after acute lymphoblastic leukemia (ALL). ALL-STAR studies prevalence, impact and risk factors for 1) self- reported adverse health outcome, 2) the metabolic syndrome, 3) reduced physical activity, 4) bone morbidity, 5) impaired immune reconstitution, 6) nephrotoxicity, and 7) psychosocial impairments and quality of life.
Background: The intensive chemotherapy used in the treatment of ALL is accompanied by infections and acute organ toxicities. The association between diagnostic characteristics, treatment, acute toxicity, and the risk of late toxicity and its risk factors, is not yet fully known.
Preliminary results: ALL-STAR is piloted in Denmark. So far, with a recruitment rate of 80%, 314 participants (survivors and controls) were included. A number of abnormal results were found in several organ systems.
Methods: Within ALL-STAR, a Nordic population-based cohort of patients who are treated according to the NOPHO ALL2008 protocol and ≥1 year after the end of therapy is established. In Sweden, 553 patients will be invited to participate. When the study closes, the whole ALL-STAR cohort is expected to include approximately 2000 eligible survivors. The participating study subjects will be invited to provide blood- and urine samples, undergo a physical exam and complete a questionnaire regarding health and quality of life. Swedish study coordinators in Lund are responsible for the studies of immune reconstitution and nephrotoxicity.
Significance: Results from the study will help to improve follow-up strategies for ALL survivors. Also, it will enable treatment modifications up future protocols to reduce treatment toxicities.
Effective start/end date2022/01/012024/12/31


  • The Swedish Childhood Cancer Fund